In recent years, we have observed a high turnover in the development of new drugs, with a failure rate of almost 84% attributed to the low efficacy/toxicity benefit.

Three therapeutic areas are most affected by this decline:
— Cancer research (failure rate of 29.5%);
—Neurology (failure rate of 14%);
—And infectious diseases (failure rate of 9.5%).

Pharmaceutical companies attribute this reduction to the transposability between in vitro and in vivo studies, highlighting the need for new predictive models.

AZELEAD responds to this need by proposing innovative solutions in these main therapeutic areas.

Our models are developed using zebrafish, a completely transparent fish that allows real time visualization of the efficacy of a drug and its side effects on the body.